Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2005 Jul 26;61(8):1031–1040. doi: 10.1107/S0907444905013090

High‐resolution structure of HLA‐A*1101 in complex with SARS nucleocapsid peptide

Thomas Blicher 1,2, Jette Sandholm Kastrup 1,2, Søren Buus 1,2, Michael Gajhede 1,2
PMCID: PMC7161638  PMID: 16041067

Abstract

The structure of the human MHC‐I molecule HLA‐A*1101 in complex with a nonameric peptide (KTFPPTEPK) has been determined by X‐ray crystallography to 1.45 Å resolution. The peptide is derived from the SARS‐CoV nucleocapsid protein positions 362–370 (SNP362–370). It is conserved in all known isolates of SARS‐CoV and has been verified by in vitro peptide‐binding studies to be a good to intermediate binder to HLA‐A*0301 and HLA‐A*1101, with IC50 values of 70 and 186 nM, respectively [Sylvester‐Hvid et al. (2004), Tissue Antigens, 63, 395–400]. In terms of the residues lining the peptide‐binding groove, the HLA‐A*1101–SNP362–370 complex is very similar to other known structures of HLA‐­A*1101 and HLA‐A*6801. The SNP362–370 peptide is held in place by 17 hydrogen bonds to the α‐chain residues and by nine water molecules which are also tightly bound in the peptide‐binding groove. Thr6 of the peptide (Thr6p) does not make efficient use of the middle (E) pocket. For vaccine development, there seems to be a potential for optimization targeted at this position. All residues except Thr2p and Lys9p are accessible for T‐cell recognition.

Keywords: coronaviruses, HLA‐A*1101, major histocompatibility complex class I, nucleocapsid proteins, SARS, vaccine development.


The full text for this article, hosted at http://journals.iucr.org, is unavailable due to technical difficulties.


Articles from Acta Crystallographica Section D: Biological Crystallography are provided here courtesy of Wiley

RESOURCES